Evidence map›Paper›PMID 25869206›Full record

ArticleOncotarget2015

Myc-dependent purine biosynthesis affects nucleolar stress and therapy response in prostate cancer.

Stefan J Barfeld, Ladan Fazli, Margareta Persson, Lisette Marjavaara, Alfonso Urbanucci, Kirsi M Kaukoniemi, Paul S Rennie, Yvonne Ceder, Andrei Chabes, Tapio Visakorpi and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 78 citations in OpenAlex.

  1. GTP biosynthesis is a therapeutic vulnerability in Rac1-mutant melanoma.bioRxiv : the preprint server for biology · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Targeting chromosomal instability in patients with cancer.Nature reviews. Clinical oncology · 2024
    Review
  16. Article
  17. Bee Venom Toxic Effect on MDA-MB-231 Breast Cancer Cells andAnti-cancer agents in medicinal chemistry · 2024
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 4 countries.

Stefan J BarfeldProstate Research Group, Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership, University of Oslo, Oslo, Norway.
Ladan FazliThe Vancouver Prostate Centre, University of British Columbia, British Columbia, Canada.
Margareta PerssonDepartment of Laboratory Medicine, Division of Clinical Chemistry, Lund University, Malmö, Sweden.
Lisette MarjavaaraDepartment of Medical Biochemistry and Biophysics, Molecular Infection Medicine Sweden (MIMS), Nordic EMBL Partnership, University of Umeå, Umeå, Sweden.
Alfonso UrbanucciProstate Research Group, Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership, University of Oslo, Oslo, Norway.
Kirsi M KaukoniemiInstitute of Biosciences and Medical Technology, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere, Finland.
Paul S RennieThe Vancouver Prostate Centre, University of British Columbia, British Columbia, Canada.
Yvonne CederDepartment of Laboratory Medicine, Division of Clinical Chemistry, Lund University, Malmö, Sweden.
Andrei ChabesDepartment of Medical Biochemistry and Biophysics, Molecular Infection Medicine Sweden (MIMS), Nordic EMBL Partnership, University of Umeå, Umeå, Sweden.
Tapio VisakorpiInstitute of Biosciences and Medical Technology, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere, Finland.
Ian G MillsProstate Research Group, Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership, University of Oslo, Oslo, Norway.
Lund University · SEUniversity of British Columbia · CAUniversity of Oslo · NOOslo University Hospital · NOTampere University · FITampere University Hospital · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The androgen receptor is a key transcription factor contributing to the development of all stages of prostate cancer (PCa). In addition, other transcription factors have been associated with poor prognosis in PCa, amongst which c-Myc (MYC) is a well-established oncogene in many other cancers. We have previously reported that the AR promotes glycolysis and anabolic metabolism; many of these metabolic pathways are also MYC-regulated in other cancers. In this study, we report that in PCa cells de novo purine biosynthesis and the subsequent conversion to XMP is tightly regulated by MYC and independent of AR activity. We characterized two enzymes, PAICS and IMPDH2, within the pathway as PCa biomarkers in tissue samples and report increased efficacy of established anti-androgens in combination with a clinically approved IMPDH inhibitor, mycophenolic acid (MPA). Treatment with MPA led to a significant reduction in cellular guanosine triphosphate (GTP) levels accompanied by nucleolar stress and p53 stabilization. In conclusion, targeting purine biosynthesis provides an opportunity to perturb PCa metabolism and enhance tumour suppressive stress responses.

Indexed as

Blotting, WesternCell NucleolusChromatin ImmunoprecipitationGene Expression Regulation, NeoplasticHumansImmunohistochemistryIMP DehydrogenaseMaleProstatic NeoplasmsProto-Oncogene Proteins c-mycPurinesReal-Time Polymerase Chain ReactionReceptors, AndrogenTissue Array AnalysisAR protein, humanIMP DehydrogenaseIMPDH2 protein, humanMYC protein, humanProto-Oncogene Proteins c-mycPurinesReceptors, Androgencancermetabolismnucleotideprostatetranscription

Identifiers

PMID25869206
PMCPMC4494960
OpenAlexW1745549119

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.